Effect of M4-cholinoceptor blockade on haloperidol-produced catatonic syndrome in rats

Bulletin of Experimental Biology and Medicine

Volumn 137, Issue 2, 2004, Pages 152-154

  Dagaev, S G ^a   Kosmachev, A B ^a   Fil'ko, O A ^a   Kubarskaya, L G ^a   Khrabrova, A V ^a   Beliaev, V A ^a   Podosinovikova, N P ^a   Libman, N M ^a   Sanotskii, V I ^a   Dolgo Saburov, V B ^a  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

Catatonia; Haloperidol; M cholinoceptor subtypes; Muscarinic receptor antagonists

Indexed keywords

AMEDIN; ANTIPARKINSON AGENT; ARECOLINE; ATROPINE; BENACTYZINE; CHOLINERGIC RECEPTOR AFFECTING AGENT; GLIPIN; HALOPERIDOL; METOCTRAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR ANTAGONIST; MUSCARINIC M2 RECEPTOR; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC M3 RECEPTOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NORGLIPIN; PENTIFYLLINE; PILOCARPINE; RECEPTOR SUBTYPE; SL 2; SL 22; SL 23; TRIHEXYPHENIDYL; TRIPERIDENE; TROPACIN; UNCLASSIFIED DRUG; LIGAND; MUSCARINIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATATONIA; CHOLINERGIC RECEPTOR BLOCKING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EXTRAPYRAMIDAL SYNDROME; LIGAND BINDING; MALE; MATHEMATICAL MODEL; NEUROPROTECTION; NONHUMAN; RAT; RECEPTOR AFFINITY; TOXICITY TESTING; ANIMAL; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DRUG ANTAGONISM; KINETICS; METABOLISM; SYNDROME;

ANIMALS; BASAL GANGLIA DISEASES; CATATONIA; HALOPERIDOL; KINETICS; LIGANDS; MALE; MODELS, BIOLOGICAL; MUSCARINIC ANTAGONISTS; PILOCARPINE; RATS; RECEPTOR, MUSCARINIC M4; RECEPTORS, MUSCARINIC; SYNDROME;

EID: 4344642233     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BEBM.0000028127.58625.f0     Document Type: Article

References (11)

1. Computer Biometrics, Ed. V. N. Nosov [in Russian], Moscow (1990).
2. A. B. Kosmachev, V. A. Beliaev, O. A. Fil'ko, et al., Eksper. Klin. Farmakol., 62, No. 4, 55-58 (1999).
3. A. B. Kosmachev, V. A. Beliaev, A. V. Khrabrova, et al., Ibid., 61, No. 5, 3-5 (1998).
4. A. B. Kosmachev, V. A. Beliaev, A. V. Khrabrova, et al., Ibid., 64, No. 4, 10-12 (2001).
5. A. B. Kosmachev, A. V. Khrabrova, A. O. Zagrebin, et al., Ibid., 63, No. 2, 21-23 (2000).
6. N. P. Podosinovikova, A. B. Kosmachev, V. D. Tonkopii, et al., Ibid., 65, No. 1, 73-74 (2002).
7. V. B. Prozorovskii, M. P. Prozorovskaya, and V. M. Demchenko, Farmakol. Toksikol., No. 2, 497 (1978).
8. V. D. Tonkopii, A. B. Kosmachev, V. V. Petrov, et al., Khim.-Farm. Zh., No. 11, 15-16 (2000).
9. V. D. Tonkopii, A. B. Kosmachev, V. V. Petrov, et al., Ibid., No. 9, 18-19 (2000).
10. A. B. Kosmachev, A. V. Khrabrova, V. A. Beliaev, et al., J. Neurochem., 71, Suppl. 1, S21 (1998).
11. J. Mayorga, G. Gianutsos, and J. D. Salamone, Brain Res., 829, 180-184 (1999).